We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Responses Better With Bosutinib vs Imatinib in Untreated CML

  • Leah Lawrence
Nov 13, 2017
  • Chronic Myeloid Leukemia, Hematologic Malignancies

Treatment with first-line bosutinib resulted in improved outcomes for patients with chronic-phase chronic myeloid leukemia (CML) compared with treatment with imatinib, according to results of the BFORE trial. Patients assigned bosutinib had a higher rate of major molecular response at 12 months, with a favorable toxicity profile. The results were published in the Journal of Clinical Oncology.

Based on these results, “bosutinib can be an important alternative for patients with previously untreated chronic-phase CML,” wrote Jorge E. Cortes, MD, of the University of Texas MD Anderson Cancer Center in Houston, and colleagues.

The phase III BFORE trial included 536 patients with newly diagnosed disease randomly assigned to 400-mg bosutinib once daily (n = 268) or imatinib (n = 268). Efficacy was assessed in patients who were Philadelphia chromosome–positive with typical transcripts.

At 12 months, 47.2% of patients assigned bosutinib achieved major molecular response compared with 36.9% of patients assigned imatinib (P = .02). Rates of major molecular response were higher with bosutinib for patients with high-, intermediate-, and low-risk Sokal risk scores. The cumulative incidence function of major molecular response was also more favorable with bosutinib than imatinib (hazard ratio [HR], 1.34; 95% CI, 1.06–1.69), which indicated a shorter time to response.

The rate of complete cytogenetic response was also higher at 12 months in patients assigned bosutinib compared with imatinib (77.2% vs 66.4%; P = .0075). Again, the cumulative incidence function of complete cytogenetic response was more favorable for bosutinib (HR, 1.38; 95% CI, 1.13–1.69).

About one-quarter of patients receiving bosutinib (22%) and imatinib (26.8%) discontinued treatment, most commonly due to drug-related toxicity (12.7% and 8.7%, respectively). However, dose interruptions were more common in patients assigned bosutinib, with 56.3% of patients having one or more dose interruptions compared with 35.8% of patients assigned imatinib. Patients assigned to bosutinib also experienced more grade 3 or worse diarrhea (7.8% vs 0.8%) and increased alanine aminotransferase (19.0% vs 1.5%) and aspartate aminotransferase (9.7% vs 1.9%) levels compared with imatinib.

“We conclude that bosutinib 400 mg once daily provides benefit over imatinib, with higher rates of cytogenetic and molecular responses, and that these responses occur earlier,” the researchers wrote. “Bosutinib is associated with a favorable toxicity profile, with most adverse events being low-grade, manageable, and improving over time.”

Related Articles

  • Duvelisib Granted Priority Review for R/R CLL/SLL and FL
  • Venetoclax/Rituximab Found Superior to Chemotherapy in CLL
  • Implications of Mutation Profiling in Myeloid Malignancies—PART 1: Myelodysplastic Syndromes and Acute Myeloid Leukemia
  • PET Imaging Helps to Predict FL Recurrence Risk
  • Targeting JAK3 and HOXA9 to Combat T-Cell ALL?

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.